Small molecules against RNA targets attract big backers

Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Small molecules against RNA targets attract big backers. Nat Rev Drug Discov 16, 813–815 (2017).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing